Skip to content

Limosilactobacillus reuteri FN041 relieves eczema in children by regulating the wnt pathway in small intestinal epithelial cells through the production of indole-3-lactic acid

Limosilactobacillus reuteri FN041 relieves eczema in children by regulating the wnt pathway in small intestinal epithelial cells through the production of indole-3-lactic acid

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088583
Enrollment
Unknown
Registered
2024-08-21
Start date
2024-09-25
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children eczema

Interventions

children FN041 intervention group:Limosilactobacillus reuteri FN041 solid drink
children DSM17938 intervention group:Limosilactobacillus reuteri DSM17938 solid drink

Sponsors

Medical College of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 10 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for children weaned as follows: (1)1~10 years old for weaned infants; (2) obvious atopic dermatitis that meets Williams criteria (symptoms lasting 4 weeks or more) with mild to moderate severity of eczema symptoms at enrollment (SCORAD index score less than 50); (3) be able to provide stool samples; (4) the child's guardian sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria for children: (1) severe eczema (SCORAD score > 50); (2) Receiving antibiotics, systemic corticosteroids, immunosuppressive or Chinese herbal therapy within 4 weeks prior to enrollment; (3) exposure to commercial probiotic products within the past 4 weeks; (4) acute gastrointestinal infection; (5) chronic underlying disease or baseline factors leading to infection (e.g., neurological, metabolic, chronic respiratory disease, congenital heart, gastrointestinal or pulmonary abnormalities); (6) Suffering from known or suspected immunodeficiency; (7) Premature birth.

Design outcomes

Primary

MeasureTime frame
scoring atopic dermatitis index;eczema area and severity index;

Secondary

MeasureTime frame
child’s dermatitis life quality index;dermatitis family impact questionnaire;

Countries

China

Contacts

Public ContactCe Qi

Medical College of Qingdao University

ceqi@qdu.edu.cn+86 181 5155 9929

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026